WGSHealthcare · Diagnostics & ResearchThe 8 Wall Street analysts covering GeneDx Holdings Corp. hold a median 12-month price target of $93 — +34.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 14 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores GeneDx Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (78): The business earns solid, repeatable profits on what it owns.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on WGS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +34.8% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $74 → $83 |
| 4 Aug 2026 | BTIG | Reiterates | Buy | — |
| 4 Aug 2026 | BTIG | Reiterates | Buy | $90 |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Buy | $75 → $90 |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 29 June 2026 | Guggenheim | Maintains | Buy | $70 → $74 |
| 29 June 2026 | Guggenheim | Maintains | Buy | — |
| 23 June 2026 | Piper Sandler | Maintains | Overweight | $50 → $63 |
| 23 June 2026 | Piper Sandler | Maintains | Overweight | — |
| 5 May 2026 | BTIG | Maintains | Buy | — |
| 5 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 May 2026 | Guggenheim | Maintains | Buy | — |
| 5 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 24 Feb 2026 | BTIG | Maintains | Buy | — |
| 24 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 9 Feb 2026 | Wells Fargo | Upgrade | Overweight | — |
| 22 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 15 Dec 2025 | Wells Fargo | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WGS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, GeneDx Holdings Corp. returned −43.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 26% of US stocks
Cheaper than 11% of US stocks
Cheaper than 95% of US stocks
Higher than 56% of US stocks
Higher than 49% of US stocks
Higher than 81% of US stocks
Higher than 23% of US stocks
Higher than 15% of US stocks
Higher than 24% of US stocks
Higher than 28% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
GeneDx Holdings Corp. has a market value of $2.0B and an enterprise value of $2.1B.
Revenue in the twelve months to 30 June 2026: $454.4M. The latest quarter grew 11.4% year on year.
Net income over the same four quarters: −$106.4M, a −23.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$75.8M.
Trailing P/E: 724.6×; forward P/E: 57.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
GeneDx Holdings Corp. employs 1,300 people — $350K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GeneDx Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
GeneDx announced that it presented new evidence on genomic newborn screening at ICoNS 2026. The provided excerpt gives no further details about the evidence.
Why it matters — The presentation relates to GeneDx’s genomic newborn screening work, an area relevant to WGS watchers.
GeneDx announced the introduction of Easy Order at AAP 2026, a tool designed to simplify genomic testing in everyday pediatric care. The announcement was made from GeneDx's headquarters in Gaithersburg, Maryland.
Why it matters — This move could broaden the use of genomic testing in routine pediatric settings, potentially expanding GeneDx's market reach within mainstream healthcare.
GeneDx and Beren Therapeutics announced the launch of NPC GenomeComplete, a new offering aimed at improving the diagnosis of Niemann-Pick Disease Type C. The announcement was made by GeneDx from its headquarters in Gaithersburg, Maryland.
Why it matters — This expansion of GeneDx's diagnostic portfolio into a specific rare disease area could broaden its testing offerings and relevance for stakeholders tracking the company's growth.
Zacks Investment Research highlighted GeneDx Holdings Corp. (WGS) alongside NEO and NTLA as promising genomics stocks for 2026, noting that these companies are advancing diagnostics and precision medicine as genomics reshapes healthcare.
Why it matters — The mention positions WGS among leading genomics companies advancing diagnostics and precision medicine, giving watchers a positive industry-level signal.
Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree in the Health Equity category, as announced in a Business Wire release. The recognition highlights her leadership at the company.
Why it matters — External recognition of the company's CEO could raise GeneDx's profile and credibility within the healthcare industry.
The 8 Wall Street analysts covering GeneDx Holdings Corp. have a median 12-month price target of $93, with estimates ranging from $83 to $103. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering GeneDx Holdings Corp., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GeneDx Holdings Corp. 46 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, GeneDx Holdings Corp. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (78 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +34.8% from the last close, and Ticker Nerd's factor model ranks GeneDx Holdings Corp. 46 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering GeneDx Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WGS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $83 to $103 over the next 12 months.
GeneDx Holdings Corp. returned -43.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
GeneDx Holdings Corp. Class A Common Stock is the equity security of GeneDx Holdings Corp., a genomics company focused on genetic testing and clinical diagnostics.
The most recent item we track (Business Wire, 7 Oct 2026): "GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026". GeneDx announced that it presented new evidence on genomic newborn screening at ICoNS 2026. The provided excerpt gives no further details about the evidence.
GeneDx Holdings Corp. Class A Common Stock is the equity security of GeneDx Holdings Corp., a genomics company focused on genetic testing and clinical diagnostics. GeneDx provides pediatric and rare disease testing centered on whole exome and whole genome sequencing, along with data and information services that support more precise diagnosis and care decisions. The company also offers AI-enabled tools for sequencing analysis, interpretation, and clinical reporting across rare disease, hereditary risk, and cancer testing. Its services are used by clinicians, hospitals, and healthcare organizations that rely on genomic information to guide patient evaluation and treatment. GeneDx Holdings Corp. plays a specialized role in the healthcare market by combining laboratory testing, bioinformatics, and clinical expertise to deliver actionable genetic insights for complex medical cases.
CEO Ms. Katherine A. Stueland · 1,300 employees · United States · https://www.genedx.com
